# CRISPR Therapeutics (CRSP) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/CRSP
## Company Profile
- Ticker: CRSP
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Switzerland with major U
- Tags: Gene Therapy
## Stock Data
- Close: 54.07 USD
- Market cap: 5017266159.84 USD
- Last updated: 2026-08-11
## Business Overview
### Gene-Based Medicine Platform
CRISPR Therapeutics develops gene-edited medicines across hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare disease. Its toolkit includes CRISPR/Cas9, the SyNTase editing platform, lipid-nanoparticle delivery and engineered cell therapies.
### CASGEVY
CASGEVY is an ex vivo CRISPR-edited autologous stem-cell therapy approved for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. Vertex leads manufacturing and commercialization, while the companies share program economics.
### In Vivo Liver Editing
The liver-directed portfolio includes CTX310 against ANGPTL3 for severe lipid disorders, CTX340 against angiotensinogen for refractory hypertension, CTX321 against LPA and CTX460 against SERPINA1 for alpha-1 antitrypsin deficiency. These programs use lipid nanoparticles to perform editing directly in patients.
### Zugo-Cel
Zugo-cel is an off-the-shelf CD19 CAR-T therapy engineered with CRISPR for immune evasion and potency. It is being evaluated across rheumatologic, hematologic and neurologic autoimmune diseases as well as B-cell malignancies.
### RNA Therapeutics
Through a collaboration with Sirius Therapeutics, the company is developing CTX611, a long-acting Factor XI siRNA for thromboembolic disorders. The candidate is in Phase 2 testing in patients undergoing total knee arthroplasty.
### Regenerative Medicine
CTX213 is a deviceless, gene-edited beta-cell replacement candidate for type 1 diabetes. The program uses edited induced pluripotent stem cells to create unencapsulated precursor islet cells intended to restore insulin production.
## Why The Stock Is Moving

As of Aug 11, 2026, CRSP closed up 1.05% at $54.07. No new same-company headline was identified in the current news window.

## Future Catalysts

- FDA review milestones for the pediatric CASGEVY submission covering patients ages 5–11.
- CTX340 clinical-trial initiation planned in the first half of 2026 and CTX460 trial initiation planned for mid-2026.
- Clinical update from the Phase 1b CTX310 program expected in the second half of 2026.
- Updates from the zugo-cel autoimmune and B-cell malignancy programs expected in the second half of 2026.
- Phase 2 CTX611 update expected in the second half of 2026.

## Recent News
- 2026-08-03 20:15 EST — [CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-second-quarter-2026-fin-cbce5bc0) — Source: CRISPR Therapeutics
- 2026-05-28 12:00 EST — [CRISPR Therapeutics to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/CRSP/crispr-therapeutics-to-participate-in-upcoming-investor-conferences) — Source: CRISPR Therapeutics
- 2026-05-06 12:30 EST — [CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference](https://biopharmsignal.com/news/CRSP/crispr-therapeutics-to-present-at-the-bank-of-america-securities-2026-global-healthcare-conference) — Source: CRISPR Therapeutics
- 2026-05-04 20:30 EST — [CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-first-quarter-2026-financial-results) — Source: CRISPR Therapeutics
- 2026-04-07 12:00 EST — [CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference](https://biopharmsignal.com/news/CRSP/crispr-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference) — Source: CRISPR Therapeutics